$7.680
-0.633 (-8.24%)收盘时
MRVI 资讯
MRVI 事件
Stock Futures Mixed as Doximity Soars 83.93%
Stock futures were mixed following a mostly lower regular session as investors continue to digest another round of corporate earnings and await news out of the Middle East.Economic data remains a central focus ahead of Friday's July employment report. Markets remain divided over the Federal Reserve's next policy move, with incoming employment data expected to play an important role in shaping expectations for interest rates over the coming months.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Doximityup 83.93%Atlassianup 32.1%Figsup 24.6%QuinStreetup 23%Cloudflareup 16.9%Twilioup 16.7%Nateraup 15.3%Akamaiup 13%Airbnbup 10.3%Instacartup 9%ALSO HIGHER -DoubleVerifyup 13.2% after Nielsen agreed to acquire the company in an all-cash transaction valued at roughly $2.15BDOWN AFTER EARNINGS -Trade Deskdown 24.5%QuidelOrthodown 21.8%Xponential Fitnessdown 12.9%Cable Onedown 9.5%Maravai Lifesciencesdown 8.8%ResMeddown 5.9%10x Genomicsdown 4.7%Dropboxdown 4.1%Post Holdingsdown 3%
TriLink BioTechnologies Granted New Patent in China
TriLink BioTechnologies, a Maravai LifeSciences company, has been granted a new patent from the China National Intellectual Property Administration, Patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules. The new patent covers TriLink's full suite of CleanCap capping analogs, including its latest M6 analog. CleanCap technology is a component of the production of synthetic mRNA as drug developers and researchers strive to maximize the impact of mRNA-based therapeutics and vaccines. The allowed claims are directed to co-transcriptional RNA synthesis methods utilizing either trimer or tetramer capping structures.
Maravai LifeSciences Opens GMP Enzyme Manufacturing Facility in Florida
TriLink, part of Maravai LifeSciences, announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production.
Maravai LifeSciences Secures $150M Loan Agreement
Maravai LifeSciences Holdings announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150M term loan facility and a $30M revolving credit facility. Borrowings under the new term loan facility, together with approximately $98.5M of cash on hand, were used to prepay outstanding borrowings under the Company's prior credit agreement due October 2027. The transaction reduces the Company's long-term debt from approximately $242.9M in aggregate outstanding principal to $150M in aggregate outstanding principal and extends the term loan maturity date to June 2032 while maintaining access to additional liquidity through the revolving credit facility.
Maravai Adjusts 2026 EBITDA Guidance to $30.0M to $32.0M
Adjusted EBITDA (non-GAAP) is now expected to be in the range of $30.0 million to $32.0 million, up from the prior range of $18.0 million to $20.0 million. Maravai's financial guidance for the full year 2026 is based on expectations for its existing business and does not include the financial impact of potential new acquisitions, if any, or items that have not yet been identified or quantified. This guidance is also subject to a number of risks, uncertainties and other factors, including those identified in "Forward-looking Statements" below.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。